Interpreting the Gastrointestinal Dysfunction Score in Clinical Practice

By
Qingdong Jia
Minjie Yuan
Shuyi Chen
Kapungo Faith
Caibao Hu
November 4, 2026

Critical Care

At a Glance

Category	Detail
Condition	Clinical topic addressed by the source article: Interpreting the Gastrointestinal Dysfunction Score in Clinical Practice
Key Mechanisms	Mechanisms or clinical associations described in the source article.
Target Population	Patients or participants described in the source article.
Care Setting	The source describes GIDS as a pragmatic, outcome-associated composite whose bedside interpretation partly reflects which components were measured.

Key Highlights

In a prospective multicentre study of 2,679 ICU patients, higher GIDS values were associated with 28- and 90-day mortality, ICU-free days, and parenteral nutrition use.
IAP and GRV measurements were often unavailable; absent measurements were classified as normal, and measurement frequency varied with illness severity and admission type.
The same numerical GIDS may represent different recorded clinical information depending on whether IAP or GRV was measured.
Sensitivity analyses supported persistence of the mortality association, but did not establish equivalent bedside meaning across measurement contexts.
Whether GIDS-directed changes in nutrition or prokinetic therapy improve outcomes remains unestablished.

Guideline-Based Recommendations

Diagnosis

The source supports GIDS as a framework for structured gastrointestinal observation and as a descriptive score associated with outcomes.
The source notes that bedside interpretation depends partly on which components were measured and recorded.

Management

The source states that whether GIDS-directed changes to enteral nutrition, prokinetic therapy, post-pyloric feeding, or parenteral nutrition improve outcomes remains unestablished.

Monitoring & Follow-up

The source recommends presenting GIDS with the measurement circumstances underlying its calculation and distinguishing pragmatic from fully measured implementations.
The source calls for prespecified, clinically justified methods for IAP and GRV ascertainment; IAP measurement should follow established consensus procedures.
The source notes that standardized outcome definitions and monitoring frameworks, including COSMOGI, may enhance cross-study comparability.

Risks

Classifying unmeasured IAP or GRV components as normal may mean identical scores reflect different sets of recorded clinical information.
The source notes that absent oral intake and prokinetic administration are influenced by clinical management, and that a high GIDS may partly capture monitoring and treatment intensity alongside underlying dysfunction.
The fully measured analysis included 311 patients for 28-day mortality and 309 for 90-day mortality; component availability did not require same-day measurement. The 90-day estimate was less precise and crossed the null (aHR 1.19, 95% CI 0.96–1.48).

Patient & Prescribing Data

The cited prospective multicentre study assessed 2,679 ICU patients. The article does not provide prescribing recommendations for a specific patient subgroup.

The relationship between GIDS and parenteral nutrition may reflect clinical decision-making. The source states that outcome benefit from GIDS-directed nutrition or prokinetic interventions is unestablished.

Clinical Best Practices

Document which GIDS components were measured, when they were measured, and how unmeasured components were handled.
Avoid assuming that identical GIDS values represent equivalent clinical states when measurement contexts differ.
For future validation, assess whether GIDS changes correspond to reproducible changes in gastrointestinal function using an independent clinical or physiological reference.